<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150176</url>
  </required_header>
  <id_info>
    <org_study_id>P05770</org_study_id>
    <secondary_id>A7501012</secondary_id>
    <nct_id>NCT00150176</nct_id>
  </id_info>
  <brief_title>To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Trial of Asenapine in the Prevention of Relapse After Long-Term Treatment of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a brain disease. The condition may be associated with acute psychotic
      episodes and long-term disability despite remission from the acute symptoms. Current
      management of schizophrenia focuses on the treatment of acute symptoms as well as long-term
      treatment aimed at preventing relapse after patients have experienced an improvement in acute
      symptoms. Patients who discontinue treatment have a high likelihood of experiencing relapse
      within 1-2 years after an acute episode of schizophrenia. Patients who remain on
      antipsychotic treatment have lower rates of relapse and have milder courses of exacerbation
      when relapse occurs.The symptoms of schizophrenia may be due to an imbalance in chemicals in
      the brain, primarily dopamine and serotonin, which enables brain cells to communicate with
      each other. Asenapine may help to correct the imbalance in dopamine and serotonin. The
      purpose of this clinical trial is to evaluate the efficacy of asenapine in preventing
      relapse/impending relapse (hereafter referred to as 'relapse') in subjects who have been
      treated with asenapine for symptoms of schizophrenia for 26 weeks. In addition, to determine
      the safety and tolerability of asenapine for up to 1-year of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse or an Impending Relapse</measure>
    <time_frame>time of first relapse up to Day 182 (double blind phase)</time_frame>
    <description>A relapse or impending relapse was declared if a subject meets 1 of 3 &quot;symptomatic relapse criteria&quot; which were all based on a combination of the Positive and Negative Syndrome Scale (PANSS) total score or PANSS items, and Clinical Global Impression-Severity (CGI-S); or if in the opinion of the investigator, the subject's symptoms of schizophrenia had deteriorated to such an extent or the risk of violence to self or others or risk of suicide had increased so that certain prespecified measures were necessary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Early Discontinuation for Any Reason</measure>
    <time_frame>time of discontinuation up to Day 182 (double blind phase)</time_frame>
    <description>The number of days to early discontinuation is the number of days from randomization to early discontinuation from the study for adverse event, relapse or impending relapse that was not considered an adverse event, withdrawal of informed consent, or lost to follow-up (without evidence of relapse).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">831</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>asenapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine - Open Label</intervention_name>
    <description>Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).</description>
    <arm_group_label>asenapine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Saphris, Org 5222, SCH 900274</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Double Blind</intervention_name>
    <description>Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine - Double Blind</intervention_name>
    <description>Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.</description>
    <arm_group_label>asenapine</arm_group_label>
    <other_name>Org 5222, SCH 900274, Saphris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Have a primary diagnosis of schizophrenia

          -  History of at least 1 prior episode of acute schizophrenia in the 3 years preceding
             screening

          -  History of schizophrenia requiring continuous antipsychotic treatment for at least 1
             years preceding screening

          -  Clinically stable at the time of entry defined by at least a 4 week period of stable
             symptoms

        Key Exclusion Criteria:

          -  Have an uncontrolled, unstable clinically significant medical condition

          -  History of suicide attempt or significant violence to others in the past 2 years

          -  A substance-induced psychotic disorder or behavioral disturbance thought to be due to
             substance abuse

          -  Current substance abuse/dependence

          -  Concurrent psychiatric disorder other than schizophrenia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Croatia</country>
    <country>India</country>
    <country>Latvia</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <results_first_submitted>April 28, 2010</results_first_submitted>
  <results_first_submitted_qc>April 28, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2010</results_first_posted>
  <disposition_first_submitted>April 29, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 2, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 6, 2009</disposition_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Prior to randomization, there was a 26 week open-label phase where 700 subjects received at least one dose of open-label asenapine (out of 831 initially enrolled). Only subjects who had continued stable presentation of symptoms during this phase were randomized into the double-blind phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Asenapine</title>
          <description>Double Blind Asenapine Group. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by asenapine 5 or 10 mg sublingual twice daily for 26 weeks in the double blind phase.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Double Blind Placebo Group. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by matching placebo sublingual twice daily for 26 weeks during the double-blind phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194">subjects who were screened and received at least one dose of double-blind trial medication</participants>
                <participants group_id="P2" count="192">subjects who were screened and received at least one dose of double-blind trial medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse/Impending relapse, non-AE</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>OTHER</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Asenapine</title>
          <description>Baseline for the double-blind period. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by asenapine 5 or 10 mg sublingual twice daily for 26 weeks in the double blind phase.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Baseline for the double-blind period. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by matching placebo sublingual twice daily for 26 weeks during the double-blind phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="194"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="386"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="12.53"/>
                    <measurement group_id="B2" value="38.7" spread="11.64"/>
                    <measurement group_id="B3" value="38.9" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Relapse or an Impending Relapse</title>
        <description>A relapse or impending relapse was declared if a subject meets 1 of 3 &quot;symptomatic relapse criteria&quot; which were all based on a combination of the Positive and Negative Syndrome Scale (PANSS) total score or PANSS items, and Clinical Global Impression-Severity (CGI-S); or if in the opinion of the investigator, the subject's symptoms of schizophrenia had deteriorated to such an extent or the risk of violence to self or others or risk of suicide had increased so that certain prespecified measures were necessary.</description>
        <time_frame>time of first relapse up to Day 182 (double blind phase)</time_frame>
        <population>ITT population, excluding subjects not treated and w/ past enrollment in an asenapine trial. As trial progressed &amp; subjects discont'd for various reasons, subjects at risk for relapse decreased from 190 each arm (Day 1) to 70 at risk in placebo arm and 135 subjects in asenapine arm (Day 182). Those relapsing &gt;3 days after last dose also excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine</title>
            <description>Double Blind Asenapine Group. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by asenapine 5 or 10 mg sublingual twice daily for 26 weeks in the double blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Placebo Group. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by matching placebo sublingual twice daily for 26 weeks during the double-blind phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse or an Impending Relapse</title>
          <description>A relapse or impending relapse was declared if a subject meets 1 of 3 &quot;symptomatic relapse criteria&quot; which were all based on a combination of the Positive and Negative Syndrome Scale (PANSS) total score or PANSS items, and Clinical Global Impression-Severity (CGI-S); or if in the opinion of the investigator, the subject's symptoms of schizophrenia had deteriorated to such an extent or the risk of violence to self or others or risk of suicide had increased so that certain prespecified measures were necessary.</description>
          <population>ITT population, excluding subjects not treated and w/ past enrollment in an asenapine trial. As trial progressed &amp; subjects discont'd for various reasons, subjects at risk for relapse decreased from 190 each arm (Day 1) to 70 at risk in placebo arm and 135 subjects in asenapine arm (Day 182). Those relapsing &gt;3 days after last dose also excluded.</population>
          <units>relapses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1 - 7 (N asenapine = 190; N placebo = 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 8 - 14 (N asenapine = 188; N placebo = 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 15 - 21 (N asenapine = 183; N placebo = 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 22 - 28 (N asenapine = 180; N placebo = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 29 - 35 (N asenapine = 175; N placebo = 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 36 - 42 (N asenapine = 175; N placebo = 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 43 - 49 (N asenapine = 173; N placebo = 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 50 - 56 (N asenapine = 166; N placebo = 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 57 - 63 (N asenapine = 165; N placebo = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 64 - 70 (N asenapine = 163; N placebo = 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 71 - 77 (N asenapine = 161; N placebo = 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 78 - 84 (N asenapine = 160; N placebo = 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 85 - 91 (N asenapine = 158; N placebo = 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 92 - 98 (N asenapine = 154; N placebo = 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 99 - 105 (N asenapine = 151; N placebo = 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 106 - 112 (N asenapine = 151; N placebo = 96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 113 - 119 (N asenapine = 149; N placebo = 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 120 - 126 (N asenapine = 147; N placebo = 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 127 - 133 (N asenapine = 147; N placebo = 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 134 - 140 (N asenapine = 146; N placebo = 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 141 - 147 (N asenapine = 145; N placebo = 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 148 - 154 (N asenapine = 142; N placebo = 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 155 - 161 (N asenapine = 141; N placebo = 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 162 - 168 (N asenapine = 139; N placebo = 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 169 - 175 (N asenapine = 137; N placebo = 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 176 - 182 (N asenapine = 135; N placebo = 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 183 - 189 (N asenapine = 75; N placebo = 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 190 - 196 (N asenapine = 9; N placebo = 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 197 - 203 (N asenapine = 2; N placebo = 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 204 - 210 (N asenapine = 0; N placebo = 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Early Discontinuation for Any Reason</title>
        <description>The number of days to early discontinuation is the number of days from randomization to early discontinuation from the study for adverse event, relapse or impending relapse that was not considered an adverse event, withdrawal of informed consent, or lost to follow-up (without evidence of relapse).</description>
        <time_frame>time of discontinuation up to Day 182 (double blind phase)</time_frame>
        <population>Intent to treat (ITT) population, additionally excluding subjects not treated and excluding subjects with past enrollment in an asenapine trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine</title>
            <description>Double Blind Asenapine Group. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by asenapine 5 or 10 mg sublingual twice daily for 26 weeks in the double blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Placebo Group. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by matching placebo sublingual twice daily for 26 weeks during the double-blind phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Early Discontinuation for Any Reason</title>
          <description>The number of days to early discontinuation is the number of days from randomization to early discontinuation from the study for adverse event, relapse or impending relapse that was not considered an adverse event, withdrawal of informed consent, or lost to follow-up (without evidence of relapse).</description>
          <population>Intent to treat (ITT) population, additionally excluding subjects not treated and excluding subjects with past enrollment in an asenapine trial.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1 - 7 (N asenapine = 191; N placebo = 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 8 - 14 (N asenapine = 190; N placebo = 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 15 - 21 (N asenapine = 184; N placebo = 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 22 - 28 (N asenapine = 181; N placebo = 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 29 - 35 (N asenapine = 176; N placebo = 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 36 - 42 (N asenapine = 176; N placebo = 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 43 - 49 (N asenapine = 173; N placebo = 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 50 - 56 (N asenapine = 166; N placebo = 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 57 - 63 (N asenapine = 166; N placebo = 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 64 - 70 (N asenapine = 163; N placebo = 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 71 - 77 (N asenapine = 162; N placebo = 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 78 - 84 (N asenapine = 162; N placebo = 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 85 - 91 (N asenapine = 158; N placebo = 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 92 - 98 (N asenapine = 153; N placebo = 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 99 - 105 (N asenapine = 150; N placebo = 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 106 - 112 (N asenapine = 150; N placebo = 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 113 - 119 (N asenapine = 149; N placebo = 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 120 - 126 (N asenapine = 148; N placebo = 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 127 - 133 (N asenapine = 148; N placebo = 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 134 - 140 (N asenapine = 146; N placebo = 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 141 - 147 (N asenapine = 145; N placebo = 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 148 - 154 (N asenapine = 142; N placebo = 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 155 - 161 (N asenapine = 141; N placebo = 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 162 - 168 (N asenapine = 139; N placebo = 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 169 - 175 (N asenapine = 137; N placebo = 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 176 - 182 (N asenapine = 135; N placebo = 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 183 - 189 (N asenapine = 75; N placebo = 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 190 - 196 (N asenapine = 9; N placebo = 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 197 - 203 (N asenapine = 2; N placebo = 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 204 - 210 (N asenapine = 0; N placebo = 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Prior to randomization to the double-blind period, there was a 26 week open-label phase where 700 subjects received at least one dose of open-label asenapine (out of 831 initially enrolled).</time_frame>
      <desc>During the first 4 weeks of the open-label period, subjects could cross titrate. The target dose of asenapine was 10 mg twice daily by week 1. Only subjects who had continued stable presentation of symptoms during open-label phase were randomized into the double-blind phase (into Asenapine or Placebo arm). Remainder of subjects were not randomized.</desc>
      <group_list>
        <group group_id="E1">
          <title>Asenapine</title>
          <description>Adverse Events for the Double Blind Period. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by asenapine 5 or 10 mg sublingual twice daily for 26 weeks in the double blind phase.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Adverse Events for the Double Blind Period. Subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1), followed by matching placebo sublingual twice daily for 26 weeks during the double-blind phase.</description>
        </group>
        <group group_id="E3">
          <title>Asenapine During Open-Label Phase and Not Randomized</title>
          <description>Adverse Events for the Open-Label period. The 'Asenapine During Open-Label Phase &amp; Not Randomized' Group includes subjects who received &gt;= 1 dose of asenapine during the 26 week open-label phase, and did NOT continue to double-blind phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ADNEXITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>EXTERNAL EAR CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SPINAL CORD INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>POOR QUALITY SLEEP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>TARDIVE DYSKINESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>UNRESPONSIVE TO STIMULI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DEPRESSIVE SYMPTOM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, AUDITORY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HOMICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PARANOIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA, PARANOID TYPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA, UNDIFFERENTIATED TYPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>THINKING ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BALANOPOSTHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>STEVENS-JOHNSON SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="170" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOAESTHESIA ORAL</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="194"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="192"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="194"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="192"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AKATHISIA</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="194"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="192"/>
                <counts group_id="E3" events="32" subjects_affected="21" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="33" subjects_affected="21" subjects_at_risk="194"/>
                <counts group_id="E2" events="28" subjects_affected="19" subjects_at_risk="192"/>
                <counts group_id="E3" events="45" subjects_affected="19" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PARKINSONISM</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="192"/>
                <counts group_id="E3" events="19" subjects_affected="12" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="43" subjects_affected="31" subjects_at_risk="194"/>
                <counts group_id="E2" events="47" subjects_affected="33" subjects_at_risk="192"/>
                <counts group_id="E3" events="65" subjects_affected="54" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="192"/>
                <counts group_id="E3" events="29" subjects_affected="24" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="194"/>
                <counts group_id="E2" events="46" subjects_affected="27" subjects_at_risk="192"/>
                <counts group_id="E3" events="48" subjects_affected="34" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DELUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="192"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="194"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="192"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="48" subjects_affected="39" subjects_at_risk="194"/>
                <counts group_id="E2" events="64" subjects_affected="47" subjects_at_risk="192"/>
                <counts group_id="E3" events="56" subjects_affected="42" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" events="32" subjects_affected="25" subjects_at_risk="192"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor will be provided an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.
Materials for intended disclosure must be provided to sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, then the disclosure must be delayed for a period not to exceed an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

